07:00 , Jun 11, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phosphoribosyl pyrophosphate synthetase 1 (PRPS1)

Cancer INDICATION: Acute lymphoblastic leukemia (ALL) In vitro studies suggest the purine synthesis inhibitor lometrexol could help treat thiopurine-resistant ALL. In ALL cells from 358 patients who relapsed after thiopurine therapy, whole-genome sequencing identified PRPS1 gain-of-function mutations...
07:00 , Jun 19, 2014 |  BC Innovations  |  Cover Story

Breaking MYC metabolism

The metabolic enzyme phosphoribosyl pyrophosphate synthetase 2 could represent a tractable way to modulate the notoriously undruggable oncogene MYC.1 The findings from a University of California, San Francisco team are licensed to Effector Therapeutics Inc....